clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2023-4-40-51clinvest-687Research ArticleОЦЕНКА ТЕХНОЛОГИЙ ЗДРАВООХРАНЕНИЯHEALTH TECHNOLOGY ASSESSMENTФармакоэкономическое исследование эффективности цитогенетических исследований у пациентов с множественной миеломой перед назначением терапии первой линииPharmacoeconomic study of the effectiveness of cytogenetic studies in patients with MM before prescribing first-line therapyhttps://orcid.org/0000-0003-2103-136XЗаболотневаЮ. А.ZabolotnevaYu. A.

Заболотнева Юлия Александровна, аспирант кафедры ЮНЕСКО «Здоровый образ жизни — залог успешного развития»

Москва

Yuliya A. Zabolotneva, post-graduate student of the UNESCO Chair “Healthy lifestyle is the key to successful development”

Moscow

ulia1984mail@gmail.comhttps://orcid.org/0000-0002-3541-1120КрысановИ. С.KrysanovI. S.

Крысанов Иван Сергеевич, к. фарм. н., доцент, заведующий лабораторией оценки технологий здравоохранения и клинико-экономической экспертизы Научно-образовательного институтафармации; заведующий курсом фармации

Москва

Ivan S. Krysanov, PhD, Cand. Sci. (Pharm.), Associate Professor, Head of the Laboratory for Assessment of Healthcare Technologies and Clinical and Economic Expertise of the Scientific and Educational Institute of Pharmacy; head of the pharmacy course

Moscow

ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Министерства здравоохранения Российской ФедерацииРоссияFSBEI НЕ «A.I. Yevdokimov Moscow State University of Medicine and Dentistry» of the Ministry of Healthcare of the Russian FederationRussian FederationФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Министерства здравоохранения Российской Федерации; Медицинский институт непрерывного образования ФГБОУ ВО «Российский биотехнологический университет»РоссияFSBEI НЕ «A.I. Yevdokimov Moscow State University of Medicine and Dentistry» of the Ministry of Healthcare of the Russian Federation; Medical Institute of Continuing Education FSBEI НЕ "Russian Biotechnological University"Russian Federation202328022024044051Copyright © Заболотнева Ю.А., Крысанов И.С., 20242024Заболотнева Ю.А., Крысанов И.С.Zabolotneva Y.A., Krysanov I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/687

Цель исследования. Проведение оценки затраты-эффективность при проведении цитогенетических исследований перед назначением различных режимов первой линии терапии множественной миеломы (ММ). Материалы и методы. Фармакоэкономическое исследование выполнено методом анализа «затраты-эффективность» в рамках Программы государственных гарантий (ПГГ). Результаты. Обзор литературы продемонстрировал, что на настоящий момент доступно ограниченное количество данных по клинической эффективности анализируемых режимов в первой линии как у пациентов с обычным, так и высоким цитогенетическим риском. Анализ «затраты-эффективность» показал, что среди трёх исследуемых схем терапии 1-ой линии (VMP, Rd, VRd) по показателю ВБП (выживаемость без прогрессии) коэффициент был минимальным для схемы VMP у пациентов высокого цитогенетического риска. Заключение. Проведённое исследование продемонстрировало, что выбор и назначение терапии первой линии в зависимости от результатов цитогенетического исследования является клинически эффективным и экономически оправданным подходом к организации медицинской помощи взрослым пациентам с множественной миеломой на территории РФ. Это может было использовано в будущем для формирования рекомендаций и стандартов оказания помощи таким пациентам в первой линии.

Purpose of the study. Conducting an assessment of the economic consequences (clinical and economic analysis) when conducting cytogenetic studies before prescribing various first-line treatment regimens for multiple myeloma (MM). Materialsand methods. The pharmacoeconomic study was carried out using the method of cost analysis, “cost-effectiveness” within the framework of the State Guarantee Program (SGP). Results. A review of the literature demonstrated that a limited number of data are currently available on the clinical effectiveness of the analyzed regimens in the first line, both in patients with normal and high cytogenetic risk. The cost-effectiveness analysis showed that among the three studied 1st-line treatment regimens (VMP, Rd, VRd), in terms of PFS (progression-free survival), the coefficient was minimal for the VMP regimen in patients with high cytogenetic risk. Conclusion. The study showed that the choice and prescription of first-line therapy, depending on the results of a cytogenetic study, is a clinically effective and cost-effective approach to organizing medical care for adult patients with multiple myeloma in the Russian Federation. This could be used in the future to formulate.

множественная миеломафармакоэкономикацитогенетические исследованияанализ затраты-эффективностьанализ затраты-полезностьанализ влияния на бюджетmultiple myelomapharmacoeconomicscytogenetic studiescost-effectiveness analysiscost-utility analysisbudget impact analysisReferencesEslick R, Talaulikar D. Multiple myeloma: from diagnosis to treatment. Aust Fam Physician. 2013 Oct;42 (10):684–8.Eslick R, Talaulikar D. Multiple myeloma: from diagnosis to treatment. Aust Fam Physician. 2013 Oct;42 (10):684–8.Cowan AJ, Allen C, Barac A, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018 Sep 1;4 (9):1221–1227. doi: 10.1001/jamaoncol.2018.2128.Cowan AJ, Allen C, Barac A, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018 Sep 1;4 (9):1221–1227. doi: 10.1001/jamaoncol.2018.2128.Cancer.net. Multiple Myeloma: Risk Factors and Prevention. 2020. Available at: https://www.cancer.net/cancer-types/multiple-myeloma/risk-factors-and-prevention. Accessed: 2020.Cancer.net. Multiple Myeloma: Risk Factors and Prevention. 2020. Available at: https://www.cancer.net/cancer-types/multiple-myeloma/risk-factors-and-prevention. Accessed: 2020.InternationalMyelomaFoundation. Roleoftransplant. 2020. Availableat: https://www.myeloma.org/autologous-stem-cell-transplant. Accessed: 03 June 2020.InternationalMyelomaFoundation. Roleoftransplant. 2020. Availableat: https://www.myeloma.org/autologous-stem-cell-transplant. Accessed: 03 June 2020.American Cancer Society. Drug Therapy for Multiple Myeloma. 2020. Available at: https://www.cancer.org/cancer/multiple-myeloma/treating/chemotherapy. html#:~:text=Using%20these%20drugs%20together%20to%20treat%20multiple%20myeloma&text=Lenalidomide%20(or%20pomalidomide%20or%20thalidomide,daratumumab)%2C%20lenalidomide%2C%20and%20dexamethasone. Accessed: 05 June 2020.American Cancer Society. Drug Therapy for Multiple Myeloma. 2020. Available at: https://www.cancer.org/cancer/multiple-myeloma/treating/chemotherapy. html#:~:text=Using%20these%20drugs%20together%20to%20treat%20multiple%20myeloma&text=Lenalidomide%20 (or%20pomalidomide%20or%20thalidomide, daratumumab)%2C%20lenalidomide%2C%20and%20dexamethasone. Accessed: 05 June 2020.Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 Jun 16;127 (24):2955–62. doi: 10.1182/blood-2016‑01‑631200.Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 Jun 16;127 (24):2955–62. doi: 10.1182/blood-2016‑01‑631200.Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10;33 (26):2863–9. doi: 10.1200/JCO.2015.61.2267.Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10;33 (26):2863–9. doi: 10.1200/JCO.2015.61.2267.Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015; 5 (10):e365. Published 2015 Oct 30. doi:10.1038/bcj.2015.92Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015; 5 (10):e365. Published 2015 Oct 30. doi:10.1038/bcj.2015.92San Miguel JF, Schlag R, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 Aug 28;359 (9):906–17. doi: 10.1056/NEJMoa0801479.San Miguel JF, Schlag R, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 Aug 28;359 (9):906–17. doi: 10.1056/NEJMoa0801479.Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008 Apr;93 (4):560–5. doi: 10.3324/haematol.12106.Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008 Apr;93 (4):560–5. doi: 10.3324/haematol.12106.Mateos MV, Richardson PG, Dimopoulos MA, et al. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015 Apr;90 (4):314–9. doi: 10.1002/ajh.23933.Mateos MV, Richardson PG, Dimopoulos MA, et al. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015 Apr;90 (4):314–9. doi: 10.1002/ajh.23933.Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010 May 1;28 (13):2259–66. doi: 10.1200/JCO.2009.26.0638.Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010 May 1;28 (13):2259–66. doi: 10.1200/JCO.2009.26.0638.Jimenez-Zepeda VH, Duggan P, Neri P, et al. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma. Ann Hematol. 2017 Mar;96 (3):431–439. doi: 10.1007/s00277‑016‑2901-x.Jimenez-Zepeda VH, Duggan P, Neri P, et al. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma. Ann Hematol. 2017 Mar;96 (3):431–439. doi: 10.1007/s00277‑016‑2901-x.Niesvizky R, Coleman M, Mark T. Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant. Oncology (Williston Park). 2010 Mar;24 (3 Suppl 2):14–21.Niesvizky R, Coleman M, Mark T. Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant. Oncology (Williston Park). 2010 Mar;24 (3 Suppl 2):14–21.Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018 Jan 18;131 (3):301–310. doi: 10.1182/blood-2017‑07‑795047.Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018 Jan 18;131 (3):301–310. doi: 10.1182/blood-2017‑07‑795047.Durie BG, Hoering A, Sexton R, et al. Longer Term Follow up of the A Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT). Blood. 2018;132 (Supplement 1).Durie BG, Hoering A, Sexton R, et al. Longer Term Follow up of the A Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT). Blood. 2018;132 (Supplement 1).Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017 Feb 4;389 (10068):519–527. doi: 10.1016/S0140–6736(16)31594-X.Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017 Feb 4;389 (10068):519–527. doi: 10.1016/S0140–6736(16)31594-X.Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020 May 11;10 (5):53. doi: 10.1038/s41408‑020‑0311‑8.Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020 May 11;10 (5):53. doi: 10.1038/s41408‑020‑0311‑8.Множественная миелома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; Москва, 2022.Multiple myeloma. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases; Moscow, 2022. (In Russ.)]. https://oncology-association.ru/wp-content/uploads/2022/04/mnozhestvennaya-mieloma.pdfHiggins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration. 2013.Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration. 2013.Отраслевой стандарт «Клинико-экономические исследования. Общие положения» [Приказ Минздрава РФ от 27.05.2002 № 163 об утверждении отраслевого стандарта «Клинико-экономические исследования. Общие положения» (вместе с ост 91500.14.0001-2002)]The industry standard "Clinical and economic research. General provisions" [Order of the Ministry of Health of the Russian Federation dated 05/27/2002 No. 163 on approval of the industry standard "Clinical and economic research. General provisions" (together with ost 91500.14.0001-2002)]. (In Russ.)Atrash S, Flahavan EM, Xu T, et al. Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. Blood Cancer J. 2022 Mar 23;12 (3):46. doi: 10.1038/s41408‑022‑00638‑0.Atrash S, Flahavan EM, Xu T, et al. Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. Blood Cancer J. 2022 Mar 23;12 (3):46. doi: 10.1038/s41408‑022‑00638‑0.Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan;11 (1):29–37. doi: 10.1016/S1470–2045(09)70284–0. Epub 2009 Oct 21. Erratum in: Lancet Oncol. 2010 Jan;11 (1):14.Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan;11 (1):29–37. doi: 10.1016/S1470–2045(09)70284–0. Epub 2009 Oct 21. Erratum in: Lancet Oncol. 2010 Jan;11 (1):14.Солодовник А. А., Мкртчян А. С., Мисюрин В. А. и др. Комплексное цитогенетическое исследование хромосомных аберраций у больных множественной миеломой. Российский биотерапевтический журнал. 2019;18 (1):50–59.Solodovnik AA, Mkrtchyan АS, Misyurin VA, et al. Complex cytogenetic research of cryptic chromosomal aberrations in patients with multiple myeloma. Russian journal of biotherapy. 2019;18 (1):50–59. (In Russ.) doi: 10.17650/1726‑9784‑2019‑18‑1‑50‑59Ягудина Р. И., Куликов А. Ю., Метелкин И. А. Методология анализа «Затраты-эффективность» при проведении фармакоэкономических исследований. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2012;5 (4):3–8.Yagudina RI, Kulikov AYu, Metelkin IA. Methodology of cost-effectiveness analysis in pharmacoeconomics. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2012;5 (4):3–8. (In Russ.) URL: https://cyberleninka.ru/article/n/metodologiya-analiza-zatratyeffektivnost-pri-provedenii-farmakoekonomicheskih-issledovaniy (дата обращения: 22.03.2023).

The authors declare that there are no conflicts of interest present.